London (ots/PRNewswire) - Eisai Europe Ltd announced today
that results from 9 clinical data abstracts about compounds in the
company's oncology pipeline, product portfolio and preclinical
oncology research have been accepted for presentation at the 44th
Annual Meeting of the American Society of Clinical Oncology (ASCO),
taking place in Chicago from May 30 to June 3, 2008.
A wide variety of abstracts on Eisai investigational compounds
will showcase research focused on metastatic breast cancer, lung
cancer, ovarian cancer, mesothelioma, pancreatic cancer and other
types of cancer, as well as supportive care to aid those currently
undergoing treatment for cancer.
"Eisai's commitment to oncology is clearly translating into the
substantial growth of our pipeline," said Haruo Naito, President and
CEO, Eisai Co., Ltd. "Eisai's focus on becoming a global leader in
oncology reflects our human health care mission to satisfy unmet
medical needs and increase benefits to patients and their families."
The following Eisai abstracts are accepted for presentation at
this year's ASCO meeting.
@@start.t1@@ Product Abstract Details Location
MORAb-003 Exploratory Phase II Efficacy Study of June 1, 2008
MORAb-003, a Monoclonal Antibody against
(farletuzumab) Folate Receptor Alpha, in 4:30-4:45
Platinum-Sensitive Ovarian Cancer in First p.m.
Abstract No: Relapse
Oral Presentation S406 (Vista
E7080 A phase I study of E7080 in patients with May 31, 2008
Abstract No: 8:00
Awarded a Foundation Merit Award W375E Lobby
E7080 Phase I dose escalation study and biomarker May 31, 2008
analysis of E7080 in patients with advanced
Abstract No: solid tumors 8:00
Poster 4 p.m.
MORAb-003 A Phase I Study of MORAb-003, a Humanized May 31, 2008
Monoclonal Antibody Against Folate Receptor
(farletuzumab) Alpha, in Advanced Epithelial Ovarian 2:00-6:00
5517 Poster 7 Location:
GCP II Glutamate Carboxypeptidase II Inhibition in May 31, 2008
Inhibitor Rat Models of Chemotherapy-induced
Peripheral Neurotoxicity 2:00-6:00
Abstract No: p.m.
9558 Poster 37A
E7820 A phase I study of E7820 in combination June 1, 2008
with cetuximab in patients (pts) with
Abstract No: advanced solid tumors 2:00-6:00
MORAb-009 A Phase I Study of MORAb-009, a Monoclonal June 1, 2008
Antibody against Mesothelin, in
Abstract No: Mesothelioma, Pancreatic, and Ovarian 2:00-6:00
3578 Cancer p.m.
Poster 27C Location: S
Eribulin Phase II Study of Eribulin June 2, 2008
Mesylate Mesylate (E7389) in Patients
(E7389) with Locally Advanced or 2:00-6:00
Abstract No: Metastatic Breast Cancer Location:
1084 Previously Treated with S Hall A1
Anthracycline, Taxane, and
Advanced Breast Oncologist and Patient Roles in June 2,
Cancer Assessing Current and Future 2008
Treatment for Metastatic Breast 2:00-6:00
Abstract No: Cancer: Results of an p.m.
1064 Observational Linguistic study Location:
Poster 32B S Hall A1@@end@@
Eisai began its oncology research program in 1987, discovering
several small molecules that are in development as chemotherapeutic
agents. In addition to its in-house oncology research and development
(R&D) program, Eisai made three strategic acquisitions to establish a
solid business infrastructure and enter the oncology market.
In October 2006, Eisai acquired four products mainly for the
treatment of cutaneous T-cell lymphoma, as well as an oncology
specialty sales force from Ligand Pharmaceuticals. This provided
Eisai with an initial commercial infrastructure for oncology
products. The acquisition of Morphotek, Inc. in April 2007 added
important antibody technology and an antibody pipeline. In January
2008, Eisai acquired MGI PHARMA, INC., an oncology and acute
care-focused company, to broaden its R&D and commercial capabilities,
pipeline and product portfolio in oncology and supportive care.
Eisai is committed to addressing the unmet medical needs of
patients with cancer and to delivering novel treatment options that
Note to Editors
About Eisai Europe Ltd.
Established in 1989, Eisai Europe Ltd. is the European
pharmaceutical subsidiary of Eisai Co. Ltd., a research-based human
health care (hhc) company that discovers, develops and markets
products throughout the world. Through a global network of research
facilities, manufacturing sites and marketing subsidiaries, Eisai
actively participates in all aspects of the worldwide health care
system. Eisai focuses its efforts in two main therapeutic areas;
integrative neurology and integrative oncology/critical care. Eisai
employs more than 9,500 people worldwide.
ots Originaltext: Eisai Europe Limited
Im Internet recherchierbar: http://www.presseportal.ch
For further information please contact: Andrew Day, Communications
Director, Eisai Europe Ltd, +44(0)208-600-1400, +44(0)7973-411-419